Literature DB >> 35773053

Evolution of Gene Therapy, Historical Perspective.

Harry L Malech1, Elizabeth K Garabedian2, Matthew M Hsieh3.   

Abstract

The earliest conceptual history of gene therapy began with the recognition of DNA as the transforming substance capable of changing the phenotypic character of a bacterium and then as the carrier of the genomic code. Early studies of oncogenic viruses that could insert into the mammalian genome led to the concept that these same viruses might be engineered to carry new genetic material into mammalian cells, including human hematopoietic stem cells (HSC). In addition to properly engineered vectors capable of efficient safe transduction of HSC, successful gene therapy required the development of efficient materials, methods, and equipment to procure, purify, and culture HSC. Increased understanding of the preparative conditioning of patients was needed to optimize the engraftment of genetically modified HSC. Testing concepts in pivotal clinical trials to assess the efficacy and determine the cause of adverse events has advanced the efficiency and safety of gene therapy. This article is a historical overview of the separate threads of discovery that joined together to comprise our current state of gene therapy targeting HSC. Published by Elsevier Inc.

Entities:  

Keywords:  Apheresis; CD34+ HSC; Gamma retrovirus vector; Gene editing; Hematopoietic stem cells; Insertional mutagenesis; Lentiviral vector; Transduction

Mesh:

Year:  2022        PMID: 35773053      PMCID: PMC9296588          DOI: 10.1016/j.hoc.2022.05.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   2.861


  97 in total

1.  The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors.

Authors:  Carolyn A Wilson; Klaus Cichutek
Journal:  Methods Mol Biol       Date:  2009

2.  Sounding boards. The potentials of inserting new genetic information.

Authors:  K E Mercola; M J Cline
Journal:  N Engl J Med       Date:  1980-11-27       Impact factor: 91.245

3.  Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments.

Authors:  T Moritz; P Dutt; X Xiao; D Carstanjen; T Vik; H Hanenberg; D A Williams
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

Review 4.  CRISPR-Cas systems for editing, regulating and targeting genomes.

Authors:  Jeffry D Sander; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-03-02       Impact factor: 54.908

5.  Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.

Authors:  Suk See De Ravin; Xiaolin Wu; Susan Moir; Sandra Anaya-O'Brien; Nana Kwatemaa; Patricia Littel; Narda Theobald; Uimook Choi; Ling Su; Martha Marquesen; Dianne Hilligoss; Janet Lee; Clarissa M Buckner; Kol A Zarember; Geraldine O'Connor; Daniel McVicar; Douglas Kuhns; Robert E Throm; Sheng Zhou; Luigi D Notarangelo; I Celine Hanson; Mort J Cowan; Elizabeth Kang; Coleen Hadigan; Michael Meagher; John T Gray; Brian P Sorrentino; Harry L Malech
Journal:  Sci Transl Med       Date:  2016-04-20       Impact factor: 17.956

6.  Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells.

Authors:  C I Civin; L C Strauss; C Brovall; M J Fackler; J F Schwartz; J H Shaper
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

7.  Chromosome-mediated gene transfer between closely realted strains of cultured mouse cells.

Authors:  G E Degnen; I L Miller; J M Eisenstadt; E A Adelberg
Journal:  Proc Natl Acad Sci U S A       Date:  1976-08       Impact factor: 11.205

8.  Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells.

Authors:  Carolina Petrillo; Lucy G Thorne; Giulia Unali; Giulia Schiroli; Anna M S Giordano; Francesco Piras; Ivan Cuccovillo; Sarah J Petit; Fatima Ahsan; Mahdad Noursadeghi; Simon Clare; Pietro Genovese; Bernhard Gentner; Luigi Naldini; Greg J Towers; Anna Kajaste-Rudnitski
Journal:  Cell Stem Cell       Date:  2018-11-08       Impact factor: 24.633

9.  Prostaglandin E2 Increases Lentiviral Vector Transduction Efficiency of Adult Human Hematopoietic Stem and Progenitor Cells.

Authors:  Garrett C Heffner; Melissa Bonner; Lauryn Christiansen; Francis J Pierciey; Dakota Campbell; Yegor Smurnyy; Wenliang Zhang; Amanda Hamel; Seema Shaw; Gretchen Lewis; Kendrick A Goss; Olivia Garijo; Bruce E Torbett; Holly Horton; Mitchell H Finer; Philip D Gregory; Gabor Veres
Journal:  Mol Ther       Date:  2017-10-05       Impact factor: 11.454

10.  Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.

Authors:  Chantal Lagresle-Peyrou; François Lefrère; Elisa Magrin; Jean-Antoine Ribeil; Oriana Romano; Leslie Weber; Alessandra Magnani; Hanem Sadek; Clémence Plantier; Aurélie Gabrion; Brigitte Ternaux; Tristan Félix; Chloé Couzin; Aurélie Stanislas; Jean-Marc Tréluyer; Lionel Lamhaut; Laure Joseph; Marianne Delville; Annarita Miccio; Isabelle André-Schmutz; Marina Cavazzana
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.